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A B S T R A C T
Objectives: To test the performance of an oral cancer prognostic 13-gene signature for the prediction of survival
of patients diagnosed with HPV-negative and p16-negative oral cavity cancer.
Materials and Methods: Diagnostic formalin-fixed paraffin-embedded oral cavity cancer tumor samples were
obtained from the Fred Hutchinson Cancer Research Center/University of Washington, University of Calgary,
University of Michigan, University of Utah, and seven ARCAGE study centers coordinated by the International
Agency of Research on Cancer. RNA from 638 Human Papillomavirus (HPV)-negative and p16-negative samples
was analyzed for the 13 genes using a NanoString assay. Ridge-penalized Cox regressions were applied to
samples randomly split into discovery and validation sets to build models and evaluate the performance of the
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T
13-gene signature in predicting 2-year oral cavity cancer-specific survival overall and separately for patients
with early and late stage disease.
Results: Among AJCC stage I/II patients, including the 13-gene signature in the model resulted in substantial
improvement in the prediction of 2-year oral cavity cancer-specific survival. For models containing age and sex
with and without the 13-gene signature score, the areas under the Receiver Operating Characteristic Curve
(AUC) and partial AUC were 0.700 vs. 0.537 (p < 0.001), and 0.046 vs. 0.018 (p < 0.001), respectively.
Improvement in predicting prognosis for AJCC stage III/IV disease also was observed, but to a lesser extent.
Conclusions: If confirmed using tumor samples from a larger number of early stage oral cavity cancer patients,
the 13-gene signature may inform personalized treatment of early stage HPV-negative and p16-negative oral
cavity cancer patients.
Introduction
Squamous cell carcinoma of the oral cavity and oropharynx (OSCC)
represents a considerable public health burden. World-wide, approxi-
mately 600,000 new cases and 325,000 deaths occurred in 2012 [1,2].
In the US, the American Cancer Society estimates that 53,000 new cases
and 10,860 deaths will occur in 2019 (https://www.cancer.org). OSCC
accounts for about 75% of the head and neck squamous cell cancers
(HNC); about two thirds of OSCC are oral cavity cancers (OCC) and one
third are oropharyngeal cancers (OPC).
HPV status is an important and independent prognostic factor for
oropharyngeal cancer. The 5-year survival under the current standard
of care, regardless of the specific therapy given, is about 80–85% for
HPV-positive but only about 30–35% for HPV-negative OPC patients
[3–7]. The discovery that HPV-positivity is associated with better sur-
vival for oropharyngeal cancer patients is clearly a breakthrough for the
HNC field, in that HPV status can be used to aid clinical management of
the oropharyngeal cancer patients. In contrast, for OCC, HPV is rela-
tively uncommon (10 to15%) and the results comparing the survival of
HPV-positive vs. HPV-negative OCC patients have been inconsistent
[8–12], and thus HPV status is not likely to be useful as a prognostic
marker[13–16]. Disease stage judged by clinicopathologic character-
istics remains the predominant feature to inform treatment and predict
prognosis. However, the ability of staging to predict prognosis in OCC is
limited; patients with tumors of the same clinical and pathologic sta-
ging have a heterogeneous response to clinical treatment and a different
probability of recurrence and survival. Patients with early stage OCC
typically undergo unimodality treatment (surgery or radiation),
whereas those with late stage disease receive multimodality treatment
(some combination of surgery, radiation, and chemotherapy) for late
stage disease. For those patients who present with early stage I/II dis-
ease treated with unimodality therapy (i.e., surgery) and for whom
neck surgery to fully assess high-risk features (multiple positive lymph
nodes, or extracapsular spread in positive lymph nodes) may not be
warranted, more precise knowledge of whether a patient’s tumor is
associated with a poor prognosis might justify treatment intensification
with a second modality (i.e., radiation +/- chemotherapy). However, at
present we lack biomarkers to identify which patients with high risk
features will respond to more aggressive treatment, and thus which
patients could be spared significant treatment toxicity.
To help improve the prediction of prognosis of OSCC patients, using
fresh tumors and Affymetrix U133 2.0 Plus GeneChip arrays, we have
previously identified a gene expression profile of 131 probe sets (re-
presenting 108 unique known genes), which not only differentiates
invasive OSCC from normal oral epithelium[17] but also predicts
OSCC-specific survival[18], with an area under the curve (AUC) of
around 0.8. Furthermore, we identified a subset of 13 genes from this
131 probe set list for which the gene expression is strongly associated
with OSCC-specific survival for patients with HPV-negative OCC and
OPC irrespective of treatment modalities, and we validated the per-
formance of this 13-gene signature in predicting survival of OCC pa-
tients using an independent dataset [19]. We report here the translation
of this finding to a potentially useful clinical test to aid in the
management of patients with HPV-negative, p16-negative OCC, by
converting the assay to the testing of formalin-fixed paraffin-embedded
(FFPE) diagnostic tumor blocks using the simple NanoString platform in
a 2-phase study. This study involved analyses of diagnostic tumor
blocks from HPV-negative and p16-negative OCC patients from the Fred
Hutchinson Cancer Research Center and the University of Washington
(FH/UW), the University of Calgary, Canada (UC), University of Mi-
chigan (UM), University of Utah (UU), and the ARCAGE study centers
in Prague, Czech Republic; Bremen, Germany; Oslo, Norway; Dublin,
Ireland; Glasgow, UK; Newcastle, UK; and Barcelona, Spain, that were
led by the International Agency of Research on Cancer (IARC), France.
This study also evaluated whether the prediction of OCC-specific sur-
vival by the expression of the 13-gene signature might be influenced by
treatment modalities (surgery alone, or multi-modality such as surgery
plus radiation, surgery plus radiation plus chemotherapy).
Materials and methods
Study population
Eligible patients had HPV16 RNA-negative and p16-im-
munohistochemistry negative primary OCC and were recruited at: FH/
UW, UM, UU, UC and seven ARCAGE Study Centers mentioned above.
Centralized pathology review for the ARCAGE study was performed by
Dr. Abedi-Ardekani of IARC.
The study is approved by the Institution Review Office of the Fred
Hutchison Cancer Research Center and that of UM, UU and UC. The
ARCAGE study was approved by the Ethical Review Board of IARC as
well as the local boards in the individual centers. All participants pro-
vided informed consent for the study.
FFPE tumor blocks prior to adjuvant therapy were selected by local
pathologists. Two consecutive 20 µm-thick FFPE curls along with two
unstained slides, or the diagnostic images of hematoxylin and eosin (H&
E) and p16 IHC, if done at local centers, were sent to the FH. H&E
staining was performed at FH Experimental Histopathology Shared
Resource. p16 IHC was performed at the UW Department of Pathology.
All H&E and p16 IHC slides and images were then centrally evaluated
by Dr. Upton, who is an anatomic pathologist at UW, to confirm the
diagnosis and to interpret p16 IHC results.
De-identified clinical data from each institution were sent to FH.
Data were reviewed and harmonized. Vital status for patients from all
institutions except IARC was updated during April 2016 to April 2017.
IARC conducted one-time retrospective follow up between 2012 and
2015 to obtain last known vital status (alive, death or lost to follow-up)
and date of last contact.
Nucleic acid extraction from FFPE samples and quality assessment
Total RNA was extracted from 20 µm-thick curls from FFPE blocks
of potentially eligible patients (N = 736) with the use of the Qiagen
RNeasy® FFPE Kit (Qiagen, Valencia, CA) following manufacturer’s
protocol. Each extraction batch contained samples from all partici-
pating institutions. RNA quantitation and purity were measured using a
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Nanodrop ND-8000 spectrophotometer (ThermoFisher Scientific,
Waltham, MA). The RNA quality was further tested by qRT-PCR on a
Life Technologies 7900 HT using the Qiagen QuantiTect SYBR® Green
RT-PCR Kit (Qiagen, Valencia, CA) with primer sets targeting LAMC2
and ACTB transcripts. For samples that failed QC (N = 153) based on
assessment on the Agilent 2200 Tapestation (Agilent, Santa Clara, CA),
an additional curl was extracted using the RNAStorm™ Kit (Cell Data
Sciences, Fremont, CA).
HPV16 RNA test
To screen samples for HPV16 RNA, we designed a probe targeting
the HPV16 E6 transcript as part of our NanoString panel. To determine
the efficacy of our newly developed NanoString probe test and to
identify the cutoff for HPV interpretation, we tested 46 samples with
known HPV16 E6 RNA status by other methodologies using our
NanoString panel. These include one HPV-positive sample from IARC
(tested by RT-PCR[20]), nine HPV-positive samples from UM (tested by
RNAscope[21]), and 26 HPV-positive and 10 HPV-negative in-house
samples, which HPV status had previously been determined by RT-PCR
as follows. Extracted total RNA was tested for HPV16 E6 expression by
qRT-PCR on a 7900 HT Sequence Detection System (Applied Biosys-
tems, Foster City, USA). In brief, a 10 µL reaction volume consisted of
200 ng of total RNA, [1X] QuantiTect® SYBR® Green RT-PCR Master
Mix (Qiagen, Valencia, USA), 0.1 µL QuantiTect® RT Mix (Qiagen,
Valencia, USA), [1 µM] forward primer 5′-GTGTACTGCAAGCAACAG
TTA-3′, and [1 µM] reverse primer 5′-TCAGGACACAGTGGCTTT
TGA-3′. Cycling conditions were: 50 °C 30 min; 95 °C 15 min; 40 cycles
of 94 °C 15 sec, 55 °C 30 sec, 72 °C 30 sec, followed by a dissociation
curve of 94 °C 15 sec, 55 °C 30 sec, 94 °C 15 sec. Expression data was
analyzed with SDS v 2.3 software (Applied Biosystems, Foster City,
USA). Samples with no amplification or the Cycle threshold (Ct) values
above 33 were defined as HPV16 RNA-negative.
The range of log2 value of HPV test on NanoString for the 10 HPV-
negative samples was 2.8 to 4.4 (mean 3.8) and for the 36 HPV-positive
samples was 9.5 to 15.5 (mean 12.9). Thus, we used the value of 7 on
log2 scale as a cutoff for HPV positivity on our NanoString test.
p16 testing by immunohistochemistry staining (IHC)
The p16 IHC was performed on unstained slides of cases from UW
(n = 203), UU (n = 88), UC (n = 181), and a portion of UM cases
(n = 62). It was performed on a Leica Bond III autostainer using a Leica
Polymer detection kit (DS-9800). The tissue sections on slides were
subjected to Heat Induced Epitope Retrieval for 20 min in EDTA buffer.
The primary p16 antibody used was a mouse monoclonal antibody from
MTM Labs catalog number 9517 at 1:4 dilution. All p16 IHC slides and
the p16 IHC images from UM (n = 85) and IARC (n = 117) were
reviewed and interpreted by Dr. Upton independent of other informa-
tion about the cases.
NanoString assay for HPV16 status and the 13-gene signature
In brief, 600 ng of total RNA was assayed with the NanoString
nCounter XT Assay (NanoString, Seattle, WA) using a custom-designed
probe sets (see Supplementary Table 1) for target genes (LIPI, C5ORF13,
CLEC3B, LAMC2, LOC283278, MYH11, OASL, OSMR, SERPINE1,
SLC16A1, THBS1, TPPP, ZDHHC11) as well as six housekeeping genes
(ALAS1, GAPDH, RPL27, RPS18, TBP, TUBA1B) and CDKN2A, and
HPV16 E6, following manufacturer’s protocol. Samples were assayed in
batches of 35 samples plus a positive control reference RNA
(XpressRef™ Universal Total RNA – Human Universal RNA (Qiagen,
Valencia, CA)) to assess batch to batch variation. To control for tech-
nical variation in hybridization efficiencies, RNA spike-in controls
provided by the manufacturer were included in each sample tested.
Samples were processed on the nCounter Prep Station and read on the
nCounter Digital Analyzer (NanoString, Seattle, WA) with FOV set at
555 following manufacturer’s instructions at the FH Genomics Shared
Resources. The NanoString probes used in this study are shown in
Supplementary Table 1.
Data processing
We first evaluated NanoString gene expression data of 724 FFPE
samples and excluded data from 23 cases due to low expression of
housekeeping genes. Results of the remaining 701 samples were nor-
malized, first according to the gene expression profile of the six spiked-
in positive control in each sample, and then to the expression levels of
the six housekeeping genes. Within each normalization step, a sample-
specific scaling factor was calculated using the geometric mean stan-
dardized over the maximum of all sample means. After the spiked-in
positive control-based normalization and housekeeping genes-based
normalization, expression data were log2 transformed. Gene level ex-
pressions were derived using the average expression levels of replicate
probes in the same gene.
Statistical analyses
For the current study, we evaluated the predictive ability of the 13-
gene signature separately for the prognosis of early stage (American
Joint Committee on Cancer (AJCC) stages I/II) and late stage (AJCC
stages III/IV) disease. Within each stage, the Ridge-penalized Cox
models were built as follows:
Model 1: survival ~ age + sex;
Model 2: survival ~ 13-gene + age + sex;
Model 3: survival ~ 13-gene + age + sex + treatment modality.
The predicted log hazard ratio (on the test data set) according to the
fitted models from the training data set were referred to as the pre-
diction scores. Specifically, the prediction scores were calculated as the
weighted sum of gene expressions, age, and gender indicator based on
the coefficients from the fitted cox regression model with ridge reg-
ularization (on the training data set). The performance of these pre-
diction models was assessed through random cross-validations with 100
iterations. In each iteration, samples were first randomly divided into
training and testing data sets with equal sample size; then a Ridge-pe-
nalized Cox proportional hazard regression model was built based on
the training data; and the prediction accuracy (Receiver Operating
Characteristic (ROC) curve) of two-year survival outcome based on the
fitted models were evaluated on the testing data. Specifically, both the
area under the curve (AUC) and partial area under the curve (pAUC) at
false positive rate (1-Specificity) of 20% were calculated to quantify the
prediction performance. Instead of full AUC, partial AUC considers only
those regions of the ROC space where data have been observed, or
which correspond to clinically relevant values of test sensitivity or
specificity. T-tests were then applied to the cross-validation AUC and
pAUC respectively to compare models with and without the 13-gene
signature.
For purpose of illustration, we chose one training–testing splitting
among the 100 random cross validation data sets, for which the testing
AUC is about the median level among all the 100 cross validation re-
sults. For the selected training–testing splitting, we divided the testing
samples into two clusters based on the predicted risk scores that are
above or below the median according to the model fitted on the training
samples. Cumulative incidence curves of OCC-specific survival of the
two clusters in the testing set were then plotted and compared through
a log-rank test. We also calculated the positive predictive value (PPV)
and negative predictive value (NPV) for death within two years post-
diagnosis for patients with stage I/II OCC in the testing set. The ana-
lyses are based on eight patients who died from OCC and 95 patients
who remained alive at two years. The analyses did not include patients
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who were lost-to-follow up (n = 7) and those who died from causes
other than oral cancer (n = 7). All the statistical analyses were con-
ducted using software R version 3.4.3.
Results
We screened FFPE tumor samples of 736 cases (FH/UW, n = 203;
UM, n = 147; UU, n = 88; UC, n = 181; IARC, n = 117). Twelve were
found to have inadequate or poor-quality RNA, and 23 failed the
NanoString assay. Of the samples from the remaining 701 cases, 638
were p16 IHC-negative and HPV16-E6 RNA negative and were retained
for the final analyses (see Supplementary Table 2). Selected char-
acteristics of these 638 study participants are shown in Table 1. The
mean age at diagnosis was 59–64 years. There were more male than
female patients in each study center. The vast majority of the patients
were White. Per Canadian law, no information on race/ethnicity was
Table 1
Selected characteristics of study participants.
FH/UW (n = 185) U Michigan (n = 138) U Utah (n = 68) U Calgary (n = 158) IARC (n = 89) Total (n = 638)
Years of Diagnosis 2004–2012 2008–2014 2004–2014 2007–2014 2002–2005 2002–2014
Age
Range 20–88 30–96 25–89 28–89 28–85 20–96
Mean, SD 60.7, 14.0 64.0, 13.8 64.0, 12.9 62.3, 13.1 58.7, 9.9 61.8, 13.2
Gender
Male 101 (54.6%) 71 (51.5%) 44 (64.7%) 101 (63.9%) 61 (68.5%) 378 (59.3%)
Female 84 (45.4%) 67 (48.5%) 24 (35.3%) 57 (36.1%) 28 (31.5%) 260 (40.7%)
Race
White 170 (92.4%) 97 (99.0%) 57 (96.6%) 0 89 (100%) 413 (96.0%)
Other 14 (7.6%) 1 (1.0%) 0 0 0 17 (4.0%)
Unknown 1 40 9 158* 0 208
Ethnicity
Hispanic 3 (1.8%) 2 (1.5%) 0 0 0 5 (1.1%)
Not Hispanic 165 (98.2%) 131 (98.5%) 57 (100.0%) 0 89 (100%) 442 (98.9%)
Unknown 17 5 11 158 0 191
Cigarette Smoking
Non-smoker 57 (30.8%) 28 (28.3%) 36 (55.4%) 41 (26.1%) 13 (14.6%) 175 (29.4%)
Former 64 (34.6%) 57 (57.6%) 10 (15.4%) 61 (38.9%) 13 (14.6%) 205 (34.5%)
Current 64 (34.6%) 14 (14.1%) 19 (29.2%) 55 (35.0%) 63 (70.8%) 215 (36.1%)
Unknown 0 39 3 1 0 43
Alcohol Use
Never 19 (10.3%) 13 (13.3%) 31 (47.7%) 28 (18.7%) 8 (9.0%) 99 (16.9%)
Former 39 (21.2%) 36 (36.7%) 4 (6.2%) 25 (16.7%) 10 (11.2%) 114 (19.5%)
Current 126 (68.5%) 49 (50.0%) 30 (46.1%) 97 (64.6%) 71 (79.8%) 373 (63.6%)
Unknown 1 40 3 8 0 52
Tumor Site
Tongue 76 (41.1%) 79 (57.3%) 27 (39.7%) 85 (53.8%) 37 (41.6%) 304 (47.6%)
Floor of Mouth 42 (22.7%) 16 (11.6%) 8 (11.8%) 26 (16.4%) 36 (40.4%) 128 (20.1%)
Buccal 14 (7.6%) 9 (6.5%) 10 (14.7%) 10 (6.3%) 1 (1.1%) 44 (6.9%)
Hard Palate 3 (1.6%) 0 2 (2.9%) 2 (1.3%) 1 (1.1%) 8 (1.3%)
Gum 35 (18.9%) 22 (15.9%) 13 (19.1%) 24 (15.2%) 7 (7.9%) 101 (15.8%)
Retromolar Trigone 14 (7.6%) 12 (8.7%) 8 (11.8%) 11 (7.0%) 7 (7.9%) 52 (8.1%)
Overlapping Site of Oral Cavity 1 (0.5%) 0 0 0 0 1 (0.2%)
AJCC Staging**
I 52 (28.1%) 38 (27.5%) 11 (16.9%) 20 (12.7%) 22 (30.2%) 143 (23.1%)
II 17 (9.2%) 20 (14.5%) 10 (15.4%) 25 (15.8%) 19 (26.0%) 91 (14.7%)
III 20 (10.8%) 25 (18.1%) 12 (18.5%) 23 (14.6%) 12 (16.4%) 92 (14.9%)
IV 96 (51.9%) 55 (39.9%) 32 (49.2%) 90 (56.9%) 20 (27.4%) 293 (47.3%)
Incomplete Data 0 0 3 0 12 19
Tumor content (%)
Range 1% − 80% 1% − 95% 1% − 90% 1% − 90% 1% − 95% 1% − 95%
Median 30% 15% 40% 30% 35% 30%
Treatment Modality
Surgery alone 81 (45.5%) 50 (37.6%) 38 (58.5%) 72 (45.6%) 32 (37.6%) 273 (44.1%)
Surgery + RT 43 (24.2%) 44 (33.1%) 16 (24.6%) 58 (36.7%) 35 (41.2%) 196 (31.7%)
Surgery + Chemo 2 (1.1%) 0 0 0 0 2 (0.3%)
Surgery + RT + Chemo 52 (29.2%) 39 (29.3%) 9 (13.8%) 28 (17.7%) 9 (10.6%) 137 (22.1%)
RT + Chemo 0 0 2 (3.1%) 0 4 (4.7%) 6 (1.0%)
RT alone 0 0 0 0 5 (5.9%) 5 (0.8%)
Incomplete Data 7 5 3 0 4 19
Vital Status
Living 73(39.5%) 90 (65.2%) 23 (33.8%) 82 (51.9%) 44 (49.4%) 312 (48.9%)
Deceased 112 (60.5%) 48 (34.8%) 45 (66.2%) 76 (48.1%) 45 (50.6%) 326 (51.1%)
Cause of Death
Oral cancer 70 (66.0%) 31 (70.4%) 18 (66.7%) 50 (65.8%) 23 (56.1%) 192 (65.3%)
Other cause 36 (34.0%) 13 (29.6%) 9 (33.3%) 26 (34.2%) 18 (43.9%) 102 (34.7%)
Unknown cause 6 4 18 0 4 32
Follow-up Time (months)
Range 0.2–145.8 1.3–88.7 0.8–155.8 0.5–114.5 0.5–130.3 0.2–155.8
Median 53.5 28.5 20.2 28.6 57.7 32.6
Median FU time for alive patients 96.1 37.2 32.6 45.8 92.6 58.6
* Per Canadian law, no information on race/ethnicity was collected from participants from the UC.
** Clinical stage used when pathological stage was not available.
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collected from participants from the UC. With the exception of UU,
most patients from other centers were either former or current cigarette
smokers and alcohol drinkers. The tongue and floor of mouth were the
most common tumor sites. A greater percentage of patients (62%
overall) had late stage (stage III/IV) disease than early stage disease.
Surgery was the most common treatment. Oral cancer was the cause of
death for about two thirds of the patients who had died prior to the end
of follow-up. The median follow-up time was 32.6 months (range
0.2–155.8 months).
Separately for patients with AJCC early stage disease (stage I/II,
n = 234) and late stage disease (stage III/IV, n = 385), we evaluated
the ability to predict 2-year OCC-specific survival through 100 random
cross-validations (see Methods section). For patients with Stage I/II
disease, Figure 1 shows the AUC and pAUC values of the testing samples
from the 100 cross-validations for the three different models, and
Figure 2 illustrates the cumulative incidence curves of high/low gene-
signature-score group based on one test data set with p-values per-
taining to comparisons between Model 1 and Model 2 (see method
section). Compared to a model with the variables age and sex, the AUC
and pAUC in a model including age, sex, and the 13-gene risk score was
considerably better in predicting 2-year survival (mean AUC 0.700 vs.
0.537, p < 0.001; mean pAUC 0.046 vs. 0.018, T test p < 0.001).
Including treatment modality in the model did not lead to any mean-
ingful change in the result (see Figure 1 for comparison between models
2 and 3). Using the median prediction score as a cut-off, individuals
with a high prediction score experienced relatively poorer OCC-specific
survival, as illustrated by the cumulative incidence curves. Similar re-
sults were observed with 5-year OCC-specific survival.
Among patients with stage I/II disease, the proposed gene signature
prediction model showed a sensitivity of 50% in predicting deaths from
OCC within 2 years when the specificity was set at 70%; the corre-
sponding positive predictive value (PPV) and negative predictive value
(NPV) were 12.5% and 94.4%, respectively. Thus, compared with an
unconditional probability of death of about 7.8%, the PPV of 12.5%
suggests that the gene signature provided a substantial improvement
(increasing PPV by about 60%) in predicting OCC-specific death. The
model based on age and sex (Model 1 in Figure 1 legend) without the
gene signature yielded a sensitivity of 13% when the specificity was set
at 70%; the corresponding PPV and NPV were 3.0% and 90.5%, re-
spectively.
The same analyses were conducted on 385 late stage (AJCC Stage
III/IV) patients. The results also showed a statistically significant im-
provement in the prediction of 2-year OCC-specific survival when
comparing the model containing 13-gene risk score plus age and sex to
a model containing age and sex alone, though the magnitude of
improvement was not as pronounced as in the early stage group. Figure
3 provides the AUC and pAUC values and depicts the comparisons of
these values among the various models. Figure 4 shows cumulative
incidence curves comparing OCC-specific survival with high and low
risk prediction score for late stage patients. A similar observation was
obtained when we included treatment modality as an additional cov-
ariate in the models (see Figure 3 for comparison between models 2 and
3). The Ridge coefficients used in the testing analyses for overall sam-
ples, early stage samples and late stage samples are presented in
Table 2.
Discussion
The 13-gene prognostic gene signature was originally discovered
and validated using fresh primary tumors obtained at the time of sur-
gical resection prior to any chemotherapy and/or radiation treatment
and using the high dimensional whole genome Affymetrix Genechip
array. The goal of the current study was to establish a prognostic gene
signature test for HPV-negative and p16-negative OCC patients using
their diagnostic FFPE tumor samples, with the hope of facilitating the
test’s eventual adoption to inform precision treatment. Our results
suggest that the 13-gene signature may help identify early stage pa-
tients who have poor likelihood of survival and who may be considered
for more aggressive treatment than surgery alone. Specifically, our
observation of modestly improved PPV and NPV values associated with
a model composed of the 13-gene-signature plus age and sex suggests
that patients who have stage I/II disease and a high risk-score may be
more likely, while those with a low risk score may be less likely, to die
within two years. While this observation might be useful to physicians
and patients to inform treatment choices, the results were based on a
relatively small number of deaths due to oral cavity cancer within two
years (n = 16) and do not permit any firm conclusion to be drawn.
Further confirmation of the findings using diagnostic tumor samples
from a larger number of OCC patients with stage I/II disease would be
warranted before the adoption of the assay in clinical settings.
The stage classification in the current study was based on AJCC
version 7 and not the recently recommended AJCC version 8[22],
which requires information on not only tumor size but also on extra-
capsular spread and depth of tumor invasion (which we did not obtain).
To what extent the 13-gene signature can improve the prediction of
survival beyond the new AJCC stage is unknown and requires in-
vestigation.
Since our discovery of a 131-gene prognostic gene signature for
OSCC in general and the 13-gene prognostic gene signature for HPV-
negative OSCC, there have been other studies that described prognostic
Fig. 1. Comparison of AUC and partial AUC of models for the prediction of 2-year OCC-specific survival among AJCC stage I & II OCC patients (n = 234). M1 (Model
1) contains age and sex; M2 (Model 2) contains expressions of the 13 genes + age + sex; and M3 (Model 3) contains expressions of the 13
genes + age + sex + treatment modality. Cross-validation was performed 100 times with samples randomly split into equal portions for training and testing
datasets. The AUC and pAUC values represent values obtained in the 100 testing datasets in the random cross validation process; the p-values in the box plots pertain
to comparisons between Model 1 and Model 2.
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Fig. 2. Results of Cumulative Incidence Curves of AJCC stage I & II OCC patients (n = 234) comparing individuals with low and high prognostic risk score in the
three prediction models as described in Fig. 1 legend. The cut-point of the high/low score clusters were the median of the risk score -0.0011 (M1), -0.022 (M2) and
-0.018 (M3). The p-values pertain to comparisons made between patients with high vs. patients with low prediction scores in each model.
Fig. 3. Comparison of AUC and partial AUC of models for the prediction of 2-year OCC-specific survival among AJCC stage III & IV OCC patients (n = 385). M1
(Model 1) contains age and sex; M2 (Model 2) contains expressions of the 13 genes + age + sex; and M3 (Model 3) contains expressions of the 13
genes + age + sex + treatment modality. Cross-validation was performed 100 times with samples randomly split into equal portions for training and testing
datasets. The AUC and pAUC values represent values obtained in the 100 testing datasets in the random cross validation process; the p-values in the box plots pertain
to comparisons between Model 1 and Model 2.
Fig. 4. Results of Cumulative Incidence Curves of AJCC stage III & IV OCC patients (n = 385) comparing individuals with low and high prognostic risk score in the
three prediction models as described in Fig. 1 legend. The cut-point of the high/low score clusters were the median of the risk score -0.029 (M1), 0.032 (M2) and
0.0031 (M3). The p-values pertain to comparisons made between patients with high vs. patients with low prediction scores in each model.
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signatures for HNC or OSCC, including some that have included
training and testing sets[23–28]. Our previously deposited datasets to
the GEO database were used either as training or validation set in some
of these studies [23,29]. There were also some prognostic signatures
reported for HNC/OSCC based on microRNA[30,31], long non-coding
RNA[32], copy number alterations of chromosomal regions[33,34],
protein markers[35] or methylation markers [25]. In addition, there
have been prognostic signatures reported on oral cancer patients whose
primary risk factors included betel quid chewing[36–38]. However,
none of these studies have restricted their efforts to HPV-negative and
p16-negative OCC, where the need for such a prediction tool is most
needed, and none have attempted to show validation of a signature that
substantially outperforms clinicopathological features. Given the het-
erogeneity of head and neck cancer with respect to risk factors, tumor
site, HPV involvement, etc., to realize a signature’s clinical utility it
would be important to evaluate how applicable a gene signature is to
the patient population for which a signature test is intended.
Ultimately, if the gene signature we have developed (or a modified
version of it) proves to be a strong enough tool in predicting survival,
clinical studies could be conducted to determine the utility of modifying
treatment recommendations based on the predicted survival: specifi-
cally, intensification of treatment in patients with a poor prognosis.
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